deltatrials
Terminated PHASE2 NCT00548327

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Atomoxetine on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype

Sponsor: National Institute of Mental Health (NIMH)

Conditions Cognition Disorders Memory Disorders Schizophrenia
Interventions Atomoxetine Functional magnetic resonance imaging Neuropsychological Testing Placebo
Updated 6 times since 2017 Last updated: Apr 30, 2013 Started: Oct 31, 2007 Primary completion: Nov 30, 2011 Completion: Nov 30, 2011

Listed as NCT00548327, this PHASE2 trial focuses on Cognition Disorders and Memory Disorders and remains terminated or withdrawn. Sponsored by National Institute of Mental Health (NIMH), it has been updated 6 times since 2007, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Mental Health (NIMH)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States